According to a new
market report published by Transparency Market Research "Hospital Acquired Disease Testing Market
(Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others) -
Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 -
2019", the global hospital
acquired disease testing market was valued at USD 2.2 billionin 2012 and is expected to grow at a
CAGR of 19.3% from 2013 to 2019, to reach an estimated value of USD 7.5
billion in 2019.
Browse the full report
with TOC at http://www.transparencymarketresearch.com/hospital-acquired-disease-testing.html
Nosocomial
infections/hospital acquired diseases/hospital associated infections (HAI)form
one of the critical areas of focus in the healthcare industry. Factors such as
increasing prevalence of such conditions in neonatal and geriatric population,
initiatives taken up by governments to manage nosocomial infections, increasing
number of diseases that increases risk of hospital associated infections, and
growing concerns about control and prevention of nosocomial infections
worldwide will have a positiveimpact on the current hospital acquired disease
testing industry.
The global hospital
acquired disease testing market is segmented on the basis of type of infection
and geography. Based on the different typesof infection,this market is
classified into pneumonia, urinary tract infection, blood stream infection,
surgical site associated infection, MRSA infection testing and others. The
hospital acquired urinary tract infection diagnostics segment occupies the
largest market share in this category as prevalence and morbidity rate of this
condition, and the demand for diagnostic solutions for the same is the highest
as compared to other hospital associated infections. It is expected that the
global market for hospital associated urinary tract infection testing will
reach USD
2,188.8 million in 2019 with the
market growing at CAGR of 18.1%from 2013 to 2019. Furthermore, other testing
solutions for conditions such as surgical site infections and pneumonia
(hospital associated and ventilator associated infections) will also experience
high demand in lesser developed regions of Asia-Pacific, Latin America and other developing countries where the
prevalence of such conditions is higher. It is expected that the market for
surgical site infections will grow at a CAGR of 20.1%during the given period of
forecast.
Geographically, United
States and Canada together are the leaders inthe global hospital
acquired disease testing market with a combined market share (of the North
American region) of 41.3% in 2012. Some of the major growth drivers for the
North American nosocomial infection testing market include existence of highly
developed healthcare infrastructure, high rate of implementation of healthcare
guidelines given by regulatory and guiding institutions such as Centers for
Disease Control and Prevention (U.S.), and increasing awareness about these
diseases and their prevention. The European Union considers infectious diseases
as an increasing threat to the general public health; the public health system
in this region is increasingly engaging itself in conducting dialogue between
healthcare providers and medical practitioners for developing better, faster
and cost effective methods for nosocomial infection management and prevention.
Asian countries including China, Philippines andIndia are the most potential markets for such diagnostic and testing
solutions owing to existence of factors such as higher population, poor
hospital infrastructure, lack of adherence to sanitation procedures and
thereforehigher disease prevalence growth rates. UAE and African countries are
some of the lucrative markets in the Rest of the World (RoW).
Molecular diagnostics
solutions play a vital role in this market as they offer precise, faster and
cost effective diagnosis for various nosocomial infections. Considering the
market competition, the global hospital acquired infection testing market is
highly fragmented and is characterized by the existence of several large and
mid-sized diagnostic solution providers. Some of the key market players
contributing to this industry include Diatherix Laboratories Inc., Gen-Probe
Inc., Qiagen GmbH, L Hoffman La Roche,Cepheid, Inc.,Life Technologies
Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc.
and others.
The global hospital
acquired disease testing market is segmented as follows:
Hospital Acquired
Disease TestingMarket, by Infection Type
§ Pneumonia infection
§ Urinary tract infection
§ Blood stream associated infection
§ Surgical site infection
§ MRSA infection
§ Others
Hospital Acquired
Disease TestingMarket, by Geography
§ North America
§ Europe
§ Asia-Pacific
§ Rest of the World
Browse all Medical Devices Market Research Reports @ http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
About Us
Transparency Market
Research is a global market intelligence company, providing global business
information reports and services. Our exclusive blend of quantitative
forecasting and trends analysis provides forward-looking insight for thousands
of decision makers. We are privileged with highly experienced team of Analysts,
Researchers, and Consultants, who use proprietary data sources and various
tools and techniques to gather, and analyze information.
Our data repository is
continuously updated and revised by a team of research experts, so that it
always reflects the latest trends and information. With a broad research and
analysis capability, Transparency Market Research employs rigorous primary and
secondary research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Blog: http://tmrreports.wordpress.com/
0 comments:
Post a Comment